골암은 뼈에 있는 세포가 통제할 수 없을 정도로 증식하는 것이 특징입니다. 뼈 조직의 유형에 따라 원발성 골암의 유형이 달라집니다. 골육종은 뼈를 형성하는 세포에서 발생하며, 유잉육종은 뼈의 미성숙한 신경 조직에서 발생합니다. 골암은 전체 암의 1% 미만을 차지하는 드문 암으로 골반과 팔과 다리의 긴 뼈에 자주 발생합니다.
세계 골암 시장은 최근 골암에 대한 CAR T 세포 치료와 같은 면역치료 기술의 도입으로 인해 괄목할 만한 성장세를 보이고 있습니다. 예를 들어 B7-H3를 표적으로 하는 CAR-T 세포는 생체 내에서 유잉육종 이종 이식편을 근절할 수 있으며, 생존율을 크게 향상시킬 수 있습니다.
또한 제품 승인 증가, 골암 치료에 대한 투자, 연구개발 등 중요한 성장 촉진요인이 향후 시장 성장을 촉진할 것으로 보입니다. 일라이 릴리(Eli Lilly and Company), 화이자(Pfizer), 마이크로바이옴 재팬(Microbiopharm Japan), 스털링 바이오텍(Sterling Biotech), 테바 파마슈티컬스 인더스트리즈(Teva Pharmaceuticals Industries Ltd.)와 같은 주요 기업이 이 시장에서 활발히 활동하고 있습니다.
세계 골암 치료 시장은 최근 다양한 연구개발로 인해 크게 성장하고 있습니다. 골암은 일반적으로 병력, 임상 소견 및 영상 소견에 따라 진단됩니다. 또한 주요 골암 치료에 대한 첨단 연구개발은 시장 성장을 가속화하는 데 도움이 되고 있습니다.
예를 들어 2023년 3월 이스트 앵글리아 대학의 연구진은 모든 주요 유형의 원발성 골암에 효과가 있는 신약을 개발했습니다. 'CADD522'라고 불리는 이 신약은 암의 확산을 촉진하는 유전자를 차단하여 수술이나 화학요법 없이도 생존율을 50% 향상시킬 수 있습니다.
또한 미국 국립보건원(National Institutes of Health)에 따르면 2022년 1월에 발표된 '진행성 연골육종의 치료 표적과 새로운 치료법'이라는 제목의 논문에 따르면 최근 연구에서 IDH1/2, COL2A1, PD-L1 등 연골육종에 대한 몇 가지 바이오마커와 치료 표적을 제시했습니다. 또한 진행성 연골육종 환자를 대상으로 한 임상 연구에서 일부 분자 표적 약물과 면역 요법이 좋은 항종양 효과를 보였습니다.
골암은 뼈에 종양이나 이형성 조직 덩어리가 형성되어 발생하며, 종양은 악성일 수도 있고 양성일 수도 있습니다. 주요 기업의 대규모 투자는 시장 성장의 원동력이 되고 있으며, 국가 기관과 기업의 이러한 효과적인 자금 지원은 연구 발견을 골암의 새로운 치료법으로 전환하는 데 도움이 되고 있습니다.
예를 들어 2023년 8월 Zetagen Therapeutics는 전이성 골암 및 연조직 종양 치료를 위한 ZetaMet 및 ZetaMAST의 발전을 위해 979만 달러의 시리즈 B 자금 조달을 확보했으며, ZetaMet은 암을 멈추고 통증을 억제하며 뼈를 재생하도록 설계된 첫 번째 분자 경로입니다.을 재생하도록 설계된 최초의 분자 경로입니다.
또한 2021년 수정등록신고서에 따르면 인히브렉스(INBX)는 보통주 매각을 통해 미화 1억 2,000만 달러의 자금 조달을 신청했습니다. 이 회사는 현재 연골 육종 및 중피종과 같은 희귀 암 및 기타 암에 대한 다양한 잠재적 치료법을 개발하고 있습니다. 따라서 위의 요인으로 인해 시장은 예측 기간 중 확대될 것으로 예상됩니다.
화학요법은 종양 세포를 파괴하거나 성장을 늦추기 위해 약물을 사용하는 널리 사용되는 암 치료법입니다. 그러나 화학요법은 신체의 건강한 세포에도 영향을 미쳐 다양한 부작용을 유발할 수 있습니다.
예를 들어 백혈병 재단은 화학요법이 모발 세포, 입, 장, 골수 조직을 구성하는 세포와 같이 빠르게 성장하는 정상 세포에 해를 끼칠 수 있다고 밝혔습니다. 또한 화학요법은 골수가 충분한 양의 혈액 세포를 생성하는 능력에 영향을 미칠 수 있으며 치료 후 1 주일 이내에 혈액 수가 감소 할 수 있습니다. 따라서 위의 요인으로 인해 시장은 예측 기간 중 침체 될 것으로 예상됩니다.
Bone cancer is characterized by the uncontrolled growth of cells in the bone. Different types of bone tissue give rise to different types of primary bone cancer. Osteosarcoma develops from cells that form the bone, and Ewing sarcoma develops from immature nerve tissue within the bone. Bone cancer is rare which makes up less than 1 percent of all cancers and commonly affects the pelvis or the long bones in the arms and legs.
The global bone cancer market has witnessed significant growth in recent years due to the adoption of immunotherapy techniques such as CAR T-cell therapy for bone cancers. For instance, B7-H3-targeted CAR-T cells can eradicate ewing sarcoma xenografts in vivo which leads to significant survival advantages.
Furthermore, significant growth drivers such as increasing product approvals, investments for bone cancer treatment, and research and developments give rise to future market growth. Significant key players like Eli Lilly and Company, Pfizer Inc., MicroBiopharm Japan Co. Ltd., Sterling Biotech Ltd., Teva Pharmaceuticals Industries Ltd., and others are actively operating in the market.
The global bone cancer treatment market has witnessed significant growth due to various recent research and developments. Bone cancer is usually diagnosed on the basis of medical history and clinical and imaging findings. Also, advanced research and developments in treating major bone cancers help to accelerate market growth.
For instance, in March 2023, researchers at the University of East Anglia developed a new drug that works against all of the main types of primary bone cancer. This new drug called 'CADD522' blocks a gene associated with driving cancer's spread and increases survival rates by 50 percent without the need for surgery or chemotherapy.
Additionally, according to the National Institue of Health, an article entitled Therapeutic Targets and Emerging Treatments in Advanced Chondrosarcoma published in January 2022 states that recent studies showed several biomarkers and therapeutic targets for chondrosarcoma including IDH1/2, COL2A1, and PD-L1. In addition, several molecule-targeting agents and immunotherapy have shown favorable antitumor activities in clinical studies of patients with advanced chondrosarcoma.
Bone cancer occurs when a tumor, or atypical mass of tissue forms in a bone, and the tumor can be malignant or benign in nature. The major investments from key companies help to drive market growth and these effective funds from national organizations and companies help to transform research discoveries into new treatments for bone cancers.
For instance, in August 2023, Zetagen Therapeutics secured a 9.79 Million USD Series B Funding raise for the advancement of ZetaMet and ZetaMAST for the treatment of metastatic bone cancers and soft tissue tumors. ZetaMet is the first molecular pathway designed to suspend cancer, inhibit pain, and regenerate bone.
Additionally, according to an amended registration statement 2021, Inhibrx (INBX) has filed to raise $102 million from the sale of its common stock. The company is currently developing a range of potential treatments for rare types of cancer such as chondrosarcoma and mesothelioma, as well as other forms of cancer. Thus, owing to the above factors the market is expected to boost over the forecast period.
Chemotherapy is a widely used cancer treatment that involves the use of drugs to destroy or slow the growth of tumor cells. Although, chemotherapy also affects healthy cells in the body which leads to various side effects.
For instance, the Leukemia Foundation states that chemotherapy can harm fast-growing normal cells, such as hair cells and cells that make up tissues in the mouth, gut, and bone marrow. Additionally, chemotherapy can impact the bone marrow's capability to generate sufficient amounts of blood cells, leading to a decrease in blood count within a week of treatment. Hence, owing to the above factors, the market is expected to hamper over the forecast period.
The global bone cancer treatment market is segmented based on type, treatment, end users, and region.
Chemotherapy is commonly used for the treatment of various cancers including bone cancers by using anti-cancer drugs to destroy the bone tumor cells. Chemotherapy is expected to hold the largest market share over the period forecast owing to increasing clinical trials conducted for bone cancers with chemotherapy treatment drugs. A total of 446 clinical trials were performed for the treatment of bone cancers with chemotherapy drugs.
For instance, according to clinicalTrials.gov, on July 3, 2023, the School of Medicine, Zhejiang University conducted a clinical trial on the Study of Surufatinib Combined With Chemotherapy as Neoadjuvant Treatment in Osteosarcoma. This study aims to explore the tumor necrosis rate in osteosarcoma patients treated with a neoadjuvant regimen of surufatinib combined with chemotherapy.
Additionally, on December 9, 2022, UNICANCER conducted a clinical trial on Mifamurtide Combined With Post-operative Chemotherapy for Newly Diagnosed High-Risk Osteosarcoma Patients. The study aims to evaluate the impact on the efficacy of mifamurtide as an add-on treatment to post-operative chemotherapy compared to post-operative chemotherapy alone in first-line treatment of patients with high-risk osteosarcoma.
The global bone cancer treatment market is segmented into North America, Europe, Asia Pacific, South America, Middle East, and Africa. North America has maintained a significant proportion of the bone cancer treatment market in recent years, and this trend is anticipated to continue throughout the forecast period due to factors such as the rising incidence of bone cancers, FDA approvals, and research and developments in bone cancer treatment.
For instance, the American Cancer Society's estimation for primary cancer of the bones and joints for 2023 is about 3,970 new cases diagnosed (2,160 in males; 1, 810 in females) and around 2,140 deaths in the United States.
In April 2023, Sumitomo Pharma Oncology, Inc. received an FDA orphan drug designation for TP-1287, an investigational oral CDK9 inhibitor, for the treatment of patients with Ewing sarcoma. TP-1287 exhibits potent inhibition of intracellular kinases including CDK9. Inhibition of CDK9 leads to downregulation of key antiapoptotic proteins such as MCL-1, which in turn has been shown to inhibit tumor growth.
The major global players in the market include: Pfizer Inc., MicroBiopharm Japan Co. Ltd., Sterling Biotech Ltd., Teva Pharmaceuticals Industries Ltd., Cipla Ltd., Aspen API Inc., Eli Lilly and Company, Gatewell Oncology Pvt. Ltd., Recordati Rare Diseases Inc., Novartis AG among others.
The COVID-19 pandemic has had a significant impact on the global bone cancer treatment market. During the height of the pandemic, many healthcare systems were overwhelmed, and non-urgent medical procedures and screenings were postponed or canceled. This led to delays in bone cancer treatment research and product launches. Clinical trials are vital for developing new treatments and improving outcomes in the bone cancer treatment market.
However, the pandemic disrupted the conduct of clinical trials, with many sites temporarily halting enrollment or modifying protocols to prioritize patient safety. This has led to delays in the completion of trials and the availability of new therapies. Moreover, the focus of research and development efforts shifted during the pandemic, with a significant emphasis on developing vaccines and treatments for COVID-19. Therefore, owing to the above factors, the bone cancer treatment market is expected to be moderately affected over the forecast period.
The global bone cancer treatment market report would provide approximately 61 tables, 60 figures, and 195 Pages.
LIST NOT EXHAUSTIVE